

STAT3 is involved in phosphatidic acid-induced Bcl-2 expression in HeLa cells

Hye-Jin Choi^{1*}, Jung Han Lee^{2*},
Shin-Young Park¹, Ju Hwan Cho¹
and Joong-Soo Han^{1,3}

¹Department of Biochemistry and Molecular Biology

²Obstetrics and Gynecology

College of Medicine

Hanyang University

Seoul 133-791, Korea

³Corresponding author: Tel, 82-2-2220-0623;

Fax, 82-2-2294-6270; E-mail, jshan@hanyang.ac.kr

*These authors contributed equally to this work.

DOI 10.3858/emm.2009.41.2.012

Accepted 29 October 2008

Abbreviations: AA, arachidonic acid; DPPA, 1,2-dipalmitoyl-sn-glycero-3-phosphate; LPA, lysophosphatidic acid; PA, phosphatidic acid; PAP, PA phosphohydrolase; STAT3, signal transducer and activator of transcription 3

Abstract

Phosphatidic acid (PA), the product of a PLD-mediated reaction, is a lipid second messenger that participates in various intracellular signaling events and is known to regulate a growing list of signaling proteins. We found that Bcl-2 was upregulated by PA treatment in HeLa cells. However, how PA upregulates Bcl-2 expression has not yet been studied. In this study, we tried to discover the mechanisms of Bcl-2 up-regulation by PA treatment in HeLa cells. Treatment with PA resulted in significantly increased expression of Bcl-2 in HeLa cells. Moreover, PA-induced Bcl-2 expression was blocked by mepacrine, an inhibitor of PLA₂, but not by propranolol, an inhibitor of PA phosphohydrolase (PAP). Treatment of 1,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA) also increased Bcl-2 expression. These results indicate that Bcl-2 expression is mediated by lysophosphatidic acid (LPA), not by arachidonic acid (AA). Thereafter, we used MEK1/2 inhibitor, PD98059 to investigate the relationship between ERK1/2 MAPK and PA-induced Bcl-2 expression. PA-induced Bcl-2 expression was decreased when ERK1/2 was inhibited by PD98059. The transcription factor such as STAT3 which is controlled by ERK1/2 MAPK was increased along with Bcl-2 expression

when the cells were treated with PA. Furthermore, STAT3 siRNA treatments inhibited PA-induced Bcl-2 expression, suggesting that STAT3 (Ser⁷²⁷) is involved in PA-induced Bcl-2 expression. Taken together, these findings indicate that PA acts as an important mediator for increasing Bcl-2 expression through STAT3 (Ser⁷²⁷) activation via the ERK1/2 MAPK pathway.

Keywords: extracellular signal-regulated MAP kinases; phosphatidic acids; phospholipases A₂; proto-oncogene proteins c-bcl-2; STAT3 transcription factor

Introduction

Phosphatidic acid (PA), a lipid second messenger, is the simplest membrane phospholipid that has been implicated in various cellular processes; including signal transduction, membrane trafficking, secretion, and cytoskeletal rearrangement. PA acts as an effective mediator which has been linked to the survival and proliferation of cells and reproduction of organisms. Indeed, exogenous PA has the same mitogenic and biological effects; including growth stimulation of fibroblasts, induction of mRNA for proto-oncogenes, growth factors, activation of the neutrophil NADPH oxidase, and binding to neutrophils (Moolenaar *et al.*, 1986; Siegmann, 1987; Knauss *et al.*, 1990; Perry *et al.*, 1993). However, the intracellular signaling mechanisms triggered by exogenously added PA are not clear.

PA has been reported to interact with a diversity of signaling molecules such as protein tyrosine kinase, ERK1/2 MAPK and phosphatidylinositol 3 kinase (Ghosh *et al.*, 1996). ERK1/2 has been involved in the regulation of a variety of cellular processes (Lee *et al.*, 2006). Recently, studies have reported that the ERK1/2 signaling pathway regulates the expression of Bcl-2 and Bcl-X_L, and promotes the survival of human pancreatic tumor cells (Boucher *et al.*, 2000). Several MAPK family members including ERK, P38 MAPK, and JNK have been identified as kinases capable of phosphorylating Ser⁷²⁷ of STAT3 (Gotoh *et al.*, 1996; Chung *et al.*, 1997; Ng and Cantrell, 1997; Lim and Cao, 1999; Turkson *et al.*, 1999; Yokogami *et al.*, 2000).

Signal transducer and activator of transcription 3 (STAT3) is a key signal molecule for many cyto-

kines and growth factor receptors (Heim *et al.*, 1999) and is activated by phosphorylation at Tyr⁷⁰⁵, which induces dimerization, nuclear translocation and DNA binding (Darnell *et al.*, 1994; Ihle, 1995). Also, STAT3 activation is also regulated by phosphorylation at Ser⁷²⁷ via the MAPK or mTOR pathway (Wen *et al.*, 1995; Yokogami *et al.*, 2000). In some studies, the STAT3 signal is mediated in survival for various tumor cell lines. Furthermore, STAT3 activation results in the upregulation of various genes involved in cell survival and proliferation; such as Bcl-2, Bcl-X_L, Mcl-1, cyclin D, and c-Myc (Zushi *et al.*, 1998; Bromberg *et al.*, 1999; Rahaman *et al.*, 2002).

In the present study, we investigated the mechanism of Bcl-2 upregulation by PA treatment. We found the effects of PA on Bcl-2 expression and obtained evidence that PA could up-regulate Bcl-2 expression by activation of ERK and phosphorylation of Ser⁷²⁷ in STAT3 in HeLa cells. These results suggest that PA is also a critical mediator in Bcl-2 up-regulation.

Results

PA increases the expression of Bcl-2 protein

To examine the effect of PA on protein expression of Bcl-2, we treated HeLa cells with various concentrations of PA for 3 h and also treated the cells with 50 μ M PA for the indicated time. The expres-

sion of Bcl-2 protein reached a maximal level at 50 μ M PA for 3 h as shown in Figure 1A and B. Based on these results, we used 50 μ M PA for 3 h for optimal conditions of PA treatment with HeLa cells in the whole experiment.

The PA-induced Bcl-2 expression was potentiated by propranolol, a PAP inhibitor, but inhibited by mepacrine, a PLA₂ inhibitor

Next, we explored the mechanism of how PA upregulates an anti-apoptotic protein, Bcl-2. PA is converted into lyso-PA (LPA) by PLA₂ or DAG by PA-phosphohydrolase (Yon *et al.*, 2003). Therefore, we checked the effect of propranolol, a well known PAP inhibitor, and mepacrine, a PLA₂ inhibitor, on mRNA and protein expression of Bcl-2. As shown in Figure 2A, PA-induced Bcl-2 expression was more greatly increased by pretreatment with propranolol. On the other hand, as shown in Figure 2B, pretreatment with mepacrine blocked PA-induced Bcl-2 mRNA and protein expression. This result suggests that PA-induced Bcl-2 mRNA and protein expression does not pass through the DAG pathway by PAP and that PLA₂ is involved in PA-induced Bcl-2 protein and mRNA expression.

DPPA leads to anti-apoptotic Bcl-2 up-regulation

PLA₂ converts PA into AA or LPA (Erickson *et al.*, 1999). To confirm which of the metabolites of PA




Figure 1. Effects of PA on the Bcl-2 expression in HeLa cells. PA increased Bcl-2 expression in both a dose- and time-dependent manner. (A) HeLa cells were cultured in DMEM containing 10% FBS; HeLa cells were further incubated without FBS for 18 h and treated with different concentrations of PA for 3 h. (B) Cells treated with 50 μ M PA for the indicated time. The relative quantities of each protein band, normalized to control cells, were quantified using Quantity One software (Bio-Rad).




Figure 2. Effects of propranolol, mepacrine, and DPPA pretreatment on the expression of Bcl-2 in HeLa cells. (A) HeLa cells were pretreated with 50 μ M propranolol for 30 min before being treated with 50 μ M PA for 30 min for RT-PCR, and for 3 h for Western blotting. (B) HeLa cells were pretreated with 50 μ M mepacrine for 30 min before 50 μ M PA treatment for 30 min for RT-PCR, and for 3 h for Western blotting, respectively. (C) HeLa cells were cultured for 1 h with 5 and 10 μ M DPPA after starvation for 18 h, respectively. The upper panel represents mRNA expression and lower panel represents protein. The cells were harvested, lysed and subjected to RT-PCR and Western blotting as described in the Methods. The relative quantities of each protein band, normalized to control cells, were quantified using Quantity One software (Bio-Rad).

contribute to the increased Bcl-2 mRNA and protein expression, we treated 1,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA), PA that has no AA, for the indicated concentrations. We found that DPPA was able to increase the Bcl-2 mRNA and protein expression, as shown in Figure 2C. As a result, LPA, not AA acted as an important metabolite for the Bcl-2 expression.

ERK1/2 MAPK and STAT3 are involved in PA-induced Bcl-2 expression

Exogenous PA has related mitogenic and biological effects. Some studies have reported that PA inter-

acts directly with the serine-threonine kinase Raf-1, an important component of the MAPK signaling cascade (Ghosh *et al.*, 1996). Recent studies report that Bcl-2 expression is under the regulation of the STAT3 in B-non-Hodgkin's lymphoma (Alas and Bonavida, 2001). We determined whether treatment with PA relates to ERK1/2 MAPK and STAT3 (Ser⁷²⁷) phosphorylation and Bcl-2 expression in HeLa cells. To confirm whether the PLA₂ pathway is crucial in ERK1/2 MAPK and STAT3 (Ser⁷²⁷) phosphorylation or Bcl-2 expression, cells were treated with mepacrine, a PLA₂ inhibitor. As a result, upon treatment with mepacrine, phosphorylation of ERK1/2 and STAT3 (Ser⁷²⁷), as well as

Bcl-2 expression after PA-stimulation, were partially reduced as shown in Figure 3A. Next we investigated whether ERK1/2 regulates PA-induced Bcl-2 expression and phosphorylation of STAT3 (Ser⁷²⁷) using PD98059, an ERK1/2 inhibitor in HeLa cells. ERK1/2 inhibitor, PD98059, inhibits the phosphorylation of STAT3 (Ser⁷²⁷) and PA-induced Bcl-2 expression, as shown in Figure 3B. These results suggest that ERK1/2 and STAT3 are located downstream of PLA₂.

Treatment of STAT3 siRNA reduces STAT3 expression and PA-induced Bcl-2 expression

To determine whether STAT3 (Ser⁷²⁷) could mediate the effect of PA-induced Bcl-2 expression we treated HeLa cells with STAT3 siRNA to knock-down STAT3 expression. Scrambled siRNA was transfected as a control. As shown in Figure 4, STAT3 siRNA decreased PA-induced Bcl-2 expression as well as expression and Ser⁷²⁷ phosphorylation of STAT3 to control levels. This result su-




Figure 3. Effects of a PLA₂ inhibitor, mepacrine, and MEK inhibitor, PD98059, on PA-induced ERK1/2, STAT3 (Ser⁷²⁷) phosphorylation, and Bcl-2 expression in HeLa cells. (A) RNA was extracted from cells pretreated with 50 μM mepacrine for 30 min, followed by stimulation with 50 μM PA for 30 min and Bcl-2 mRNA was amplified by RT-PCR. HeLa cells were pretreated with 50 μM mepacrine for 30 min, followed by stimulation with 50 μM PA for 15 min. Cell lysates were analyzed by immunoblotting with anti-ERK1/2, anti-STAT3, and phospho-ERK1/2, phospho-STAT3 (Ser⁷²⁷) antibodies. In the case of Bcl-2 Western blotting, cells were pretreated with 50 μM mepacrine for 30 min, followed by stimulation with 50 μM PA for 3 h. Cell lysates were analyzed by immunoblotting with Bcl-2 antibody. (B) RNA was extracted from cells treated with 50 μM PD98059 for 1 h, followed by stimulation with 50 μM PA for 30 min and Bcl-2 mRNA was amplified by RT-PCR. HeLa cells were pretreated with 50 μM PD98059 for 1 h, followed by stimulation with 50 μM PA for 15 min. Cell lysates were analyzed by immunoblotting with anti-ERK1/2, STAT3, and phospho-ERK1/2, STAT3 (Ser⁷²⁷) antibodies. In the case of Bcl-2 Western blotting, cells were pretreated with 50 μM PD98059 for 1 h, followed by stimulation with 50 μM PA for 3 h. Cell lysates were analyzed by immunoblotting with Bcl-2 antibody. The relative quantities of each protein band, normalized to control cells, were quantified using Quantity One software (Bio-Rad).




Figure 4. Effects of STAT3 siRNA on the expression of Bcl-2 in HeLa cells. HeLa cells were transiently transfected with 100 nM STAT3 siRNA or scramble siRNA for 72 h and then stimulated with 50 μ M PA for 15 min (for p-STAT3/STAT3 blots) or 3 h (for Bcl-2 blots). Expression level of p-STAT3 (Ser⁷²⁷), STAT3, and Bcl-2 were determined by Western blot analysis. The relative quantities of each protein band, normalized to control cells, were quantified using Quantity One software (Bio-Rad).

ports that STAT3 (Ser⁷²⁷) is directly related to PA-induced Bcl-2 expression.

Discussion

Bcl-2, a proto-oncogene, was first identified as an oncoprotein coded by a gene translocation of chromosomes 14:18 and induced in follicular B-cell lymphomas (Tsujiyama *et al.*, 1985). Bcl-2 prevents IL-3-dependent cells from apoptotic death upon withdrawal of the cytokine (Vaux *et al.*, 1988). Members of the Bcl-2 family are classified as antiapoptotic factors, which include Bcl-2, Bcl-xL, Mcl-1, and others. The proapoptotic members can be separated into two subgroups: the Bax subfamily (Bax, Bak and Bok), which contain multiple BH domains, and the BH3-only family including Bad, Bid, Bim, Noxa, Hrk, and others (Huang and Strasser, 2000; Adams and Cory, 2001; Newmeyer and Ferguson-Miller, 2003; Tsujimoto, 2003; Choi *et al.*, 2006). Bcl-2 protein is the most important regulator




Figure 5. A proposed model for the signaling pathway of PA-induced Bcl-2 expression. We diagramed a mechanism of up-regulation of Bcl-2 expression induced by PA. PA can be converted to LPA by PLA₂, but does not pass through the DAG pathway by PAP. Subsequently, LPA acts as an important signal molecule to upregulate Bcl-2 expression. PA leads to activation of downstream kinases, ERK1/2, which are responsible for the phosphorylation of STAT3 (Ser⁷²⁷).

of apoptosis and is involved in the regulation of the cell cycle (O'Reilly *et al.*, 1997), prolongs cell survival (Korsmeyer, 1992), and inhibits apoptosis (O'Reilly *et al.*, 1997). Several studies have reported that Bcl-2 modulates cell differentiation (Lu *et al.*, 1995) and gene expression (Miyashita *et al.*, 1995) and also regulates the transactivity of several transcription factors such as NF- κ B (Ricca *et al.*, 2000), and p53 (Froesch *et al.*, 199). Furthermore Bcl-2 regulates outer mitochondrial membrane permeability and release of cytochrome C and other apoptogenic factors (Huang and Strasser, 2000; Adams and Cory, 2001; Newmeyer and Ferguson-Miller, 2003; Tsujimoto, 2003; Choi *et al.*, 2006). Previously, we reported that PA produced by PLD raises Bcl-2 protein expression in several cells lines (Oh *et al.*, 2007; Cho *et al.*, 2008). However, how PA regulates Bcl-2 expression has not been studied yet.

When we treated HeLa cells with PA, Bcl-2 expression was increased in both a dose- and time-dependent manner. However PA did not show any effect on the expression of another antiapoptotic protein, such as Bcl-xL (data not shown). PA can be degraded into arachidonic acid (AA) and lyso-PA (LPA) by PLA₂. AA, a polyunsaturated fatty acid, can be converted to prostaglandin by cyclooxygenase (COX) (Herrmann *et al.*, 1997). To find out whether PLA₂, a product of PA, was involved in the increased expression of Bcl-2 in HeLa cells, we used DPPA, which has two palmitic acids instead of AA. DPPA treatment also increased Bcl-2 expression, indicating that LPA, not AA, is an important mediator in down stream of PA for the induction of Bcl-2 expression.

Recently, the MAPK cascade, which is well known for cell proliferation and differentiation including cell

signaling, were studied to be associated with the apoptotic pathway (Kim *et al.*, 2003). Ghosh *et al.* (1996) first proposed that PA is a regulator of the ERK phosphorylation cascade. ERK, P38 MAPK, and JNK have been identified as kinases capable of phosphorylating serine 727 of STAT3 (Gotoh *et al.*, 1996; Chung *et al.*, 1997; Ng and Cantrell, 1997; Lim and Cao, 1999; Turkson *et al.*, 1999; Yokogami *et al.*, 2000). Indeed, the transcriptional activity of STAT3 via Ser⁷²⁷ phosphorylation was modulated by ERK (Chung *et al.*, 1997). Interestingly, STAT3 is an important transcription factor for the regulation of Bcl-2 gene expression in B-non-Hodgkin's lymphoma (Alas and Bonavida, 2001). To establish the relationship between PA and ERK1/2/STAT3 (Ser⁷²⁷), we examined whether the ERK1/2 and STAT3 (Ser⁷²⁷) were activated by PA. We found that activation of ERK1/2 and STAT3 (Ser⁷²⁷) through PA treatment are completely abolished by pretreatment with mepacrine, a PLA₂ inhibitor. The inhibition of MEK1/2 by PD98059 also led to the suppression of PA-induced Bcl-2 expression and phosphorylation of STAT3 (Ser⁷²⁷). We further investigated the involvement of STAT3 (Ser⁷²⁷) in Bcl-2 up-regulation by using STAT3 siRNA. As expected, knockdown of STAT3 showed a decrease in PA-induced Bcl-2 expression. These results strongly suggest that activation of ERK1/2 and STAT3 (Ser⁷²⁷) were closely related to the PA-induced Bcl-2 expression pathway.

Taken together, results in the present study indicate that PA acts as an important regulator during Bcl-2 up-regulation in HeLa cells. On top of this result, LPA is also responsible for increasing PA-induced Bcl-2 expression in HeLa cells through activating ERK1/2 and STAT3.

Methods

Materials

FBS, penicillin/streptomycin solution, and DMEM with L-glutamine and low glucose were purchased from Gibco-BRL (MD). Bcl-2 monoclonal antibody and GAPDH polyclonal antibody were obtained from Santa Cruz Biotechnology (CA). ERK1/2 polyclonal antibody and p-ERK1/2 monoclonal antibody, STAT3 polyclonal antibody and p-STAT3 (Ser⁷²⁷) polyclonal antibody were obtained from Cell signaling (MA). Propranolol and mepacrine were purchased from Sigma-Aldrich (MO). 1,2-dipalmitoyl-sn-glycero-3-phosphate (DPPA) was purchased from Avanti Polar Lipids (Alabaster, AL). 1,2-dioctanoly-sn-glycerol-3-phosphate sodium salt (PA) was purchased from Sigma-Aldrich (MO). PD98059 was purchased from Calbiochem (CA).

Cell culture

HeLa cells were incubated for 2 days at 37°C in DMEM

supplemented with 10% (v/v) heated-inactivated FBS, 100 units/ml penicillin, and 100 µg/ml streptomycin. Cells were grown at 37°C in a humidified CO₂-controlled (5%) incubator, then washed with DMEM medium containing 0.1% (w/v) BSA, 100 units/ml penicillin, and 100 µg/ml streptomycin (serum-free medium) and incubated in a serum-free medium at 37°C for 18 h before treatment.

Reverse transcriptase polymerase chain reaction (RT-PCR)

cDNA was made from total mRNA extracted from cells. Total cellular RNA was isolated using Trizol reagent (Life Technologies Inc., Rockville, MD) according to the manufacturer's instructions. For the reverse transcriptase reaction, 5 µg of total RNA was mixed with oligo (dT)₁₆ primer and Maloney murine leukemia virus (M-MLV) reverse transcriptase (Promega, Madison, WI), and the mixture was incubated for 60 min at 42°C. The transcribed products were mixed with each primer set and *Taq* DNA polymerase (Takara Shuzo, Japan), and then amplified. Bcl-2 sense 5'-CATTTCACGTC AACAGAATTG-3' and antisense 5'-AGCACAGGATTGGATATTCAT-3 (PCR product, 505bp): GAPDH sense: 5'-GCTCAGACACCATGGGGAAGGT-3' and antisense: 5'-GTGGTGCAGGAGGCAT-TGCTGA (PCR product, 473 bp). The PCR products were analyzed in 1.2% agarose-gel.

Western blot analysis

Cells were washed twice with ice-cold PBS and scraped in PBS, then harvested by microcentrifugation. The cells were then resuspended in 0.5 ml of lysis buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1 mM NAF, 1 mM Na₃VO₄, 1 mM PMSF, 1% Triton X-100, 0.5% NP-40, 10 µg/ml aprotinin, 10 µg/ml leupeptin) on ice and disrupted by sonication. Cell lysates were centrifuged for 10 min at 10,000 × *g* at 4°C. Proteins (30 µg of protein/lane) from control or treated cells were resolved by SDS-PAGE and transferred to nitrocellulose membranes using a Bio-Rad semi-dry transfer system. The membranes were blocked for 1 h with 5% (v/v) non-fat milk in TTBS (trisbuffered saline containing 0.1% Tween 20) and then incubated with diluted specific antibody (1 µg/ml) for another hour. Unbound primary antibodies were removed by three washes (5 min each) with TTBS. The membranes were then incubated with HRP-coupled goat anti-rabbit or antimouse IgG (diluted 1:1000 with TTBS; KPL, Gaithersburg, MD) for 1 h, followed by three washes (5 min each) in TTBS. Visualization of signals was achieved by using chemiluminescence (ECL reagent, Amersham Biosciences) according to the manufacturer's protocol. Protein concentrations were routinely determined by the Bradford procedure with Bio-Rad dye reagent and BSA as a standard.

Small interference RNA (siRNA) synthesis and transfection

Human STAT3 siRNA was purchased from Ambion (Austin, TX). A human STAT3 sequence (sense: 5'-AACUUC-

AGACCCGUCAACAAAdTdT-3'; antisense 5'-UUUGUU-GACGGGUCUGAAGUUDdT-3') was chosen for STAT3 RNAi targeting. The siRNA was transiently transfected into the HeLa cell (3×10^5 cells/well; 6-well plate) using the NeoFX reagent and 72 h after transfection, the cells were harvested for Western blotting. A negative control was carried out with Negative Control siRNA#2 (from Ambion).

Statistical analysis

All experiments were performed at least three times in triplicate, and results were expressed as mean value of \pm SD. The significance of differences were assessed by an unpaired *t*-test.

Acknowledgements

This work was supported by the research fund of Hanyang University (HY-2004-N), and the Korea Science and Engineering Foundation (KOSEF) grant funded by the Korea government (MEST) (R13-2008-026-01000-0).

References

Adams JM, Cory S. Life-or-death decisions by the Bcl-2 protein family. *Trends Biochem Sci* 2001;26:61-6

Alas S, Bonavida B. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs. *Cancer Res* 2001;61:5137-44

Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X (L), and Mcl-1 and promotes survival of human pancreatic cancer cells. *J Cell Biochem* 2000;79:355-69

Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell JE Jr. Stat3 as an oncogene. *Cell* 1999;98:295-303

Cho JH, Hong SK, Kim EY, Park SY, Park CH, Kim JM, Kwon OJ, Kwon SJ, Lee KS, Han JS. Overexpression of phospholipase D suppresses taxotere-induced cell death in stomach cancer cells. *Biochim Biophys Acta* 2008;1783:912-23

Choi YK, Kim TK, Kim CJ, Lee JS, Oh SY, Joo HS, Foster DN, Hong KC, You S, Kim H. Activation of the intrinsic mitochondrial apoptotic pathway in swine influenza virus-mediated cell death. *Exp Mol Med* 2006;38:11-7

Chung J, Uchida E, Grammer TC, Blenis J. STAT3 serine phosphorylation by ERK-dependent and -independent pathways negatively modulates its tyrosine phosphorylation. *Mol Cell Biol* 1997;17:6508-16

Darnell JE Jr, Kerr IM, Stark GR. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 1994;264:1415-21

Erickson RW, Langel-Peveri P, Traynor-Kaplan AE, Hey-

worth PG, Curnutte JT. Activation of human neutrophil NADPH oxidase by phosphatidic acid or diacylglycerol in a cell-free system. Activity of diacylglycerol is dependent on its conversion to phosphatidic acid. *J Biol Chem* 1999;274:22243-50

Froesch BA, Aime-Sempe C, Leber B, Andrews D, Reed JC. Inhibition of p53 transcriptional activity by Bcl-2 requires its membrane-anchoring domain. *J Biol Chem* 1999;274:6469-75

Ghosh S, Strum JC, Sciorra VA, Daniel L, Bell RM. Raf-1 kinase possesses distinct binding domains for phosphatidylserine and phosphatidic acid. Phosphatidic acid regulates the translocation of Raf-1 in 12-O-tetradecanoylphorbol-13-acetate-stimulated Madin-Darby canine kidney cells. *J Biol Chem* 1996;271:8472-80

Gotoh A, Takahira H, Mantel C, Litz-Jackson S, Boswell HS, Broxmeyer HE. Steel factor induces serine phosphorylation of Stat3 in human growth factor-dependent myeloid cell lines. *Blood* 1996;88:138-45

Heim MH. The Jak-STAT pathway: cytokine signalling from the receptor to the nucleus. *J Recept Signal Transduct Res* 1999;19:75-120

Herrmann JL, Menter DG, Beham A, von Eschenbach A, McDonnell TJ. Regulation of lipid signaling pathways for cell survival and apoptosis by bcl-2 in prostate carcinoma cells. *Exp Cell Res* 1997;234:442-51

Huang DC, Strasser A. BH3-Only proteins-essential initiators of apoptotic cell death. *Cell* 2000;103:839-42

Ihle JN. Cytokine receptor signaling. *Nature* 1995;377:591-4

Kim HJ, Yang SJ, Kim YS, Kim TU. Cobalt chloride-induced apoptosis and extracellular signal-regulated protein kinase activation in human cervical cancer HeLa cells. *J Biochem Mol Biol* 2003;36:468-74

Knauss TC, Jaffer FE, Abboud HE. Phosphatidic acid modulates DNA synthesis, phospholipase C, and platelet-derived growth factor mRNAs in cultured mesangial cells. Role of protein kinase C. *J Biol Chem* 1990;265:14457-63

Korsmeyer SJ. Bcl-2 initiates a new category of oncogenes: regulators of cell death. *Blood* 1992;80:879-86

Lee DY, Lee MW, Lee HJ, Noh YH, Park SC, Lee MY, Kim KY, Lee WB, Kim SS. ERK1/2 activation attenuates TRAIL-induced apoptosis through the regulation of mitochondria-dependent pathway. *Toxicol In Vitro* 2006;20:816-23

Lim CP, Cao X. Serine phosphorylation and negative regulation of Stat3 by JNK. *J Biol Chem* 1999;274:31055-61

Lu PJ, Lu QL, Rughetti A, Taylor-Papadimitriou J. Bcl-2 overexpression inhibits cell death and promotes the morphogenesis, but not tumorigenesis of human mammary epithelial cells. *J Cell Biol* 1995;129:1363-78

Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC. Overexpression of the Bcl-2 protein increases the half-life of p21Bax. *J Biol Chem* 1995;270:26049-52

Moolenaar WH, Kruiger W, Tilly BC, Verlaan I, Bierman AJ, de Laat SW. Growth factor-like action of phosphatidic acid. *Nature* 1986;323:171-3

Newmeyer DD, Ferguson-Miller S. Mitochondria: releasing power for life and unleashing the machineries of death. *Cell* 2003;112:481-90

Ng J, Cantrell D. STAT3 is a serine kinase target in T lymphocytes. Interleukin 2 and T cell antigen receptor signals converge upon serine 727. *J Biol Chem* 1997;272:24542-9

Oh KJ, Lee SC, Choi HJ, Oh DY, Kim SC, Min DS, Kim JM, Lee KS, Han JS. Role of phospholipase D2 in anti-apoptotic signaling through increased expressions of Bcl-2 and Bcl-xL. *J Cell Biochem* 2007;101:1409-22

O'Reilly LA, Harris AW, Strasser A. Bcl-2 transgene expression promotes survival and reduces proliferation of CD3-CD4-CD8- T cell progenitors. *Int Immunol* 1997;9:1291-301

Perry DK, Stevens VL, Widlanski TS, Lambeth JD. A novel ecto-phosphatidic acid phosphohydrolase activity mediates activation of neutrophil superoxide generation by exogenous phosphatidic acid. *J Biol Chem* 1993;268:25302-10

Rahaman SO, Harbor PC, Chernova O, Barnett GH, Vogelbaum MA, Haque SJ. Inhibition of constitutively active Stat3 suppresses proliferation and induces apoptosis in glioblastoma multiforme cells. *Oncogene* 2002;21:8404-13

Ricca A, Biroccio A, Del Bufalo D, Mackay AR, Santoni A, Cippitelli M. Bcl-2 over-expression enhances NF-kappaB activity and induces mmp-9 transcription in human MCF7 (ADR) breast-cancer cells. *Int J Cancer* 2000;86:188-96

Siegmann DW. Stimulation of quiescent 3T3 cells by phosphatidic acid-containing liposomes. *Biochim Biophys Res Commun* 1987;145:228-33

Tsujimoto Y, Cossman J, Jaffe E, Croce CM. Involvement of the bcl-2 gene in human follicular lymphoma. *Science* 1985;228:1440-3

Tsujimoto Y. Cell death regulation by the Bcl-2 protein family in the mitochondria. *J Cell Physiol* 2003;195:158-67

Turkson J, Bowman T, Adnane J, Zhang Y, Djeu JY, Sekharam M, Frank DA, Holzman LB, Wu J, Sehti S, Jove R. Requirement for Ras/Rac1-mediated p38 and c-Jun N-terminal kinase signaling in Stat3 transcriptional activity induced by the Src oncoprotein. *Mol Cell Biol* 1999;19:7519-28

Vaux DL, Cory S, Adams JM. Bcl-2 gene promotes haemopoietic cell survival and cooperates with c-myc to immortalize pre-B cells. *Nature* 1988;335:440-2

Wen Z, Zhong Z, Darnell JE Jr. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. *Cell* 1995;82:241-50

Yokogami K, Wakisaka S, Avruch J, Reeves SA. Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR. *Curr Biol* 2000;10:47-50

Yon C, Lee MH, Oh DY, Kim DS, Lee KS, Han JS. Advanced lipid extraction method for the determination of the phospholipase D activity. *Arch Pharm Res* 2003;26:478-81

Zushi S, Shinomura Y, Kiyohara T, Miyazaki Y, Kondo S, Sugimachi M, Higashimoto Y, Kanayama S, Matsuzawa Y. STAT3 mediates the survival signal in oncogenic ras-transfected intestinal epithelial cells. *Int J Cancer* 1998;78:326-30